

# Charles D Pusey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3077226/publications.pdf>

Version: 2024-02-01

148  
papers

12,816  
citations

41344

49  
h-index

23533

111  
g-index

173  
all docs

173  
docs citations

173  
times ranked

6859  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel model of nephrotic syndrome results from a point mutation in Lama5 and is modified by genetic background. <i>Kidney International</i> , 2022, 101, 527-540.	5.2	5
2	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. <i>Scientific Reports</i> , 2022, 12, 3330.	3.3	5
3	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. <i>BMJ, The</i> , 2022, 376, e064604.	6.0	42
4	The authors reply:. <i>Kidney International</i> , 2022, 101, 648-649.	5.2	2
5	Glomerulonephritis and autoimmune vasculitis are independent of <scp>P2RX7</scp> but may depend on alternative inflammasome pathways. <i>Journal of Pathology</i> , 2022, 257, 300-313.	4.5	3
6	Membranous nephropathy associated with viral infection. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 876-883.	2.9	14
7	Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. <i>Kidney International</i> , 2021, 99, 488-489.	5.2	8
8	Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1181.	4.1	2
9	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	1.9	20
10	Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. <i>Rheumatology</i> , 2021, , .	1.9	7
11	Characterisation of an enhanced preclinical model of experimental MPOâ€ANCA autoimmune vasculitis. <i>Journal of Pathology</i> , 2021, 255, 107-119.	4.5	4
12	A Comparison of Pulsatile Hypothermic and Normothermic Ex Vivo Machine Perfusion in a Porcine Kidney Model. <i>Transplantation</i> , 2021, 105, 1760-1770.	1.0	10
13	New Insights into Epidemiology and Outcome of Bacterial Infectionâ€Related Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1149-1151.	4.5	0
14	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , 2021, 100, 1316-1324.	5.2	26
15	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 739-742.	0.7	6
16	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
17	Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 313-324.	1.4	4
18	MO004THE SAFETY PROFILE OF REPEAT RITUXIMAB TREATMENT IN ANCA-ASSOCIATED VASCULITIS - A 10 YEAR SINGLE CENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0

#	ARTICLE	IF	CITATIONS
19	A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa048.	0.2	16
20	Nasal reconstructive surgery for vasculitis affecting the nose: our two-centre international experience. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 3059-3066.	1.6	5
21	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines—Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	1.9	5
22	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	1.9	42
23	Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. <i>Kidney International</i> , 2020, 97, 1196-1207.	5.2	34
24	Membranous Glomerulonephritis With Crescents. <i>Kidney International Reports</i> , 2019, 4, 1577-1584.	0.8	16
25	220. DEFINING THE PATHOGENESIS OF ANCA AND ANTI-GBM DOUBLE POSITIVITY. <i>Rheumatology</i> , 2019, 58, .	1.9	0
26	260. LONG TERM OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS PRESENTING WITH SEVERE RENAL DYSFUNCTION. <i>Rheumatology</i> , 2019, 58, .	1.9	0
27	Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. <i>BMC Nephrology</i> , 2019, 20, 352.	1.8	6
28	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). <i>Kidney International Reports</i> , 2019, 4, 1342-1348.	0.8	6
29	Dr. Kang, et al. reply. <i>Journal of Rheumatology</i> , 2019, 46, 1244.2-1244.	2.0	0
30	Dr. Kang, et al. reply. <i>Journal of Rheumatology</i> , 2019, 46, 866.2-867.	2.0	0
31	Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background. <i>Scientific Reports</i> , 2019, 9, 20398.	3.3	11
32	Plasma exchange in anti-glomerular basement membrane disease. <i>Presse Medicale</i> , 2019, 48, 328-337.	1.9	9
33	High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 285-293.	2.0	38
34	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 63-73.	0.7	96
35	Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. <i>Scientific Reports</i> , 2018, 8, 53.	3.3	9
36	Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. <i>Kidney International</i> , 2018, 94, 139-149.	5.2	73

#	ARTICLE	IF	CITATIONS
37	TESTING Corticosteroids in IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 158-160.	4.5	16
38	Antiglomerular Basement Membrane Disease. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 494-503.	2.1	21
39	Peroxidasinâ€™a Novel Autoantigen in Anti-GBM Disease?. Journal of the American Society of Nephrology: JASN, 2018, 29, 2605.2-2607.	6.1	2
40	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. Journal of Clinical Apheresis, 2018, 33, 638-644.	1.3	12
41	Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. F1000Research, 2018, 7, 1113.	1.6	12
42	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 2018, 94, 926-936.	5.2	3
43	Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 63-72.	4.5	72
44	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. CKJ: Clinical Kidney Journal, 2017, 10, sfw116.	2.9	37
45	The natural history of immunoglobulin M nephropathy in adults. Nephrology Dialysis Transplantation, 2017, 32, gfw063.	0.7	12
46	IgA1 Glycosylation Is Heritable in Healthy Twins. Journal of the American Society of Nephrology: JASN, 2017, 28, 64-68.	6.1	27
47	The Histopathological Classification of ANCA-associated Glomerulonephritis Comes of Age. Journal of Rheumatology, 2017, 44, 265-267.	2.0	12
48	Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrology Dialysis Transplantation, 2017, 32, i123-i128.	0.7	33
49	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival,â€™frequency of relapse, and outcomes compared to single-seropositive patients. Kidney International, 2017, 92, 693-702.	5.2	154
50	Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1162-1172.	4.5	259
51	Is there a role for TNFÎ± blockade in ANCA-associated vasculitis and glomerulonephritis?. Nephrology Dialysis Transplantation, 2017, 32, i80-i88.	0.7	17
52	Crescentic glomerulonephritis: beyond the immune system. Nature Reviews Nephrology, 2017, 13, 198-200.	9.6	5
53	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic featuresâ€™renal biopsy. Kidney International, 2017, 92, 1223-1231.	5.2	55
54	CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuleepithelial cells. BMC Nephrology, 2016, 17, 139.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. <i>Rheumatology</i> , 2016, 55, 1437-1442.	1.9	34
56	A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. <i>Autoimmunity Reviews</i> , 2016, 15, 577-584.	5.8	82
57	The role of monocytes in ANCA-associated vasculitides. <i>Autoimmunity Reviews</i> , 2016, 15, 1046-1053.	5.8	34
58	Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1324-1326.	4.5	13
59	Familial vasculitides: granulomatosis with polyangiitis and microscopic polyangiitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 429-431.	2.9	7
60	Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome. <i>Stem Cells and Development</i> , 2016, 25, 395-404.	2.1	18
61	ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. <i>PLoS ONE</i> , 2016, 11, e0165402.	2.5	21
62	Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. <i>Journal of Immunology</i> , 2015, 195, 2343-2352.	0.8	37
63	SURVEY OF STAFF OPINIONS ABOUT EXTENDED HAEMODIALYSIS TREATMENT TIME AND SERVICE IMPLICATIONS. <i>Journal of Renal Care</i> , 2015, 41, 162-167.	1.2	0
64	Local IL-17 Production Exerts a Protective Role in Murine Experimental Glomerulonephritis. <i>PLoS ONE</i> , 2015, 10, e0136238.	2.5	11
65	FP721 RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii317-iii317.	0.7	0
66	Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by $\alpha$ 3 autoantigen complementarity <sup>TM</sup> . <i>Journal of Autoimmunity</i> , 2015, 59, 8-18.	6.5	14
67	Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 1262-1268.	5.2	53
68	Rituximab for maintenance of remission in AAV. <i>Nature Reviews Nephrology</i> , 2015, 11, 131-132.	9.6	6
69	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. <i>Kidney International</i> , 2015, 88, 52-60.	5.2	34
70	Clinical and Imaging Features of Lacrimal Gland Involvement in Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 2125-2129.	5.2	19
71	Tissue Interleukin-17 and Interleukin-23 as Biomarkers for Orbital Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 2140-2142.	5.2	9
72	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1128-1135.	4.5	75

#	ARTICLE	IF	CITATIONS
73	S100A8/A9 (Calprotectin) Is Critical for Development of Glomerulonephritis and Promotes Inflammatory Leukocyte-Renal Cell Interactions. <i>American Journal of Pathology</i> , 2015, 185, 1264-1274.	3.8	36
74	Macrophage Epoxygenase Determines a Profibrotic Transcriptome Signature. <i>Journal of Immunology</i> , 2015, 194, 4705-4716.	0.8	28
75	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. <i>Rheumatology</i> , 2015, 54, 1025-1032.	1.9	12
76	Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. <i>Rheumatology</i> , 2015, 54, 899-907.	1.9	29
77	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. <i>Kidney International</i> , 2015, 87, 807-811.	5.2	23
78	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1185-1192.	0.7	94
79	The heterogeneous mononuclear phagocyte system of the kidney. <i>Kidney International</i> , 2014, 85, 1011-1014.	5.2	5
80	Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 1693-1703.	1.9	59
81	Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2291-2302.	6.1	46
82	Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1350-1361.	0.7	24
83	Goodpasture Syndrome and Other Antiglomerular Basement Membrane Diseases. , 2014, , 193-197.		0
84	Clinical and Imaging Features Predictive of Orbital Granulomatosis with Polyangiitis and the Risk of Systemic Involvement. <i>Ophthalmology</i> , 2014, 121, 1304-1309.	5.2	52
85	Issues in trial design for ANCA-associated and large-vessel vasculitis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 502-510.	8.0	7
86	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1571-1576.	4.5	53
87	L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture's disease). <i>Presse Medicale</i> , 2013, 42, 625-628.	1.9	3
88	B-cell-targeted therapy in adult glomerulonephritis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1691-1706.	3.1	11
89	Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. <i>Kidney International</i> , 2013, 83, 1150-1158.	5.2	86
90	Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1343-1350.	0.7	26

#	ARTICLE	IF	CITATIONS
91	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2012, 51, 634-643.	1.9	102
92	Genetic Susceptibility to Experimental Autoimmune Glomerulonephritis in the Wistar Kyoto Rat. <i>American Journal of Pathology</i> , 2012, 180, 1843-1851.	3.8	13
93	Plasmapheresis in Immunologic Renal Disease. <i>Blood Purification</i> , 2012, 33, 190-198.	1.8	43
94	Genetically Distinct Subsets within ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2012, 367, 214-223.	27.0	820
95	Crescentic Glomerulonephritis: New Aspects of Pathogenesis. <i>Seminars in Nephrology</i> , 2011, 31, 361-368.	1.6	55
96	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.9	719
97	Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3280-3286.	0.7	58
98	Ocular manifestations of Wegener's granulomatosis. <i>Expert Review of Ophthalmology</i> , 2011, 6, 541-555.	0.6	7
99	Management of ANCA-associated vasculitis: Current trends and future prospects. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 253.	2.0	37
100	Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2209-2217.	0.7	200
101	Histopathologic Classification of ANCA-Associated Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1628-1636.	6.1	681
102	Kallikreins: unravelling the genetics of autoimmune glomerulonephritis*. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2987-2989.	0.7	0
103	Renal & Ocular Targets for Therapy in Wegeners Granulomatosis. <i>Inflammation and Allergy: Drug Targets</i> , 2009, 8, 70-79.	1.8	5
104	Goodpasture's Syndrome and Other Anti-Glomerular Basement Membrane Disease. , 2009, , 186-190.		0
105	Regulation of inflammation and scarring in glomerulonephritis. <i>International Journal of Experimental Pathology</i> , 2008, 85, A14-A14.	1.3	0
106	Ocular manifestations of Wegener's granulomatosis. <i>Expert Review of Ophthalmology</i> , 2007, 2, 91-103.	0.6	4
107	Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2180-2188.	6.1	973
108	Drug Insight: rituximab in renal disease and transplantation. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 221-230.	2.0	114

#	ARTICLE	IF	CITATIONS
109	Is There a Role for TNF- $\alpha$ in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1243-1252.	6.1	61
110	Therapeutic Effect of Anti-TNF- $\alpha$ Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibody-Associated Systemic Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 160-169.	6.1	98
111	The Continuing Challenge of Anti-Neutrophil Cytoplasm Antibody-Associated Systemic Vasculitis and Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1221-1223.	6.1	5
112	Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. <i>Blood</i> , 2005, 106, 2050-2058.	1.4	246
113	Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management. <i>Nephrology</i> , 2005, 10, 368-376.	1.6	24
114	Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2761-2768.	0.7	94
115	Prospective Study of TNF- $\alpha$ Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 717-721.	6.1	345
116	Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. <i>Kidney International</i> , 2004, 66, 1535-1540.	5.2	284
117	Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. <i>American Journal of Kidney Diseases</i> , 2003, 41, 776-784.	1.9	435
118	Anti-glomerular basement membrane disease. <i>Kidney International</i> , 2003, 64, 1535-1550.	5.2	187
119	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. <i>Kidney International</i> , 2003, 64, 1685-1694.	5.2	102
120	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. <i>American Journal of Clinical Pathology</i> , 2003, 120, 312-318.	0.7	167
121	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	27.0	1,239
122	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases. <i>American Journal of Clinical Pathology</i> , 2003, 120, 312-318.	0.7	86
123	Immunology of anti-glomerular basement membrane disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 279-286.	2.0	32
124	Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis. <i>American Journal of Pathology</i> , 2002, 161, 1265-1272.	3.8	35
125	Segregation of Experimental Autoimmune Glomerulonephritis as a Complex Genetic Trait and Exclusion of <i>Col4a3</i> as a Candidate Gene. <i>Nephron Experimental Nephrology</i> , 2002, 10, 402-407.	2.2	23
126	Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. <i>American Journal of Kidney Diseases</i> , 2002, 39, 1162-1167.	1.9	143



#	ARTICLE	IF	CITATIONS
127	Anti-CD8 Monoclonal Antibody Therapy Is Effective in the Prevention and Treatment of Experimental Autoimmune Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 359-369.	6.1	81
128	Goodpasture's disease. <i>Lancet</i> , The, 2001, 358, 917-920.	13.7	155
129	Long-Term Outcome of Anti-“Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression. <i>Annals of Internal Medicine</i> , 2001, 134, 1033.	3.9	503
130	Cellular aspects of vasculitis “ T cell-mediated aspects. <i>Seminars in Immunopathology</i> , 2001, 23, 287-298.	4.0	3
131	Multisorbent Plasma Perfusion in Fulminant Hepatic Failure: Effects of Duration and Frequency of Treatment in Rats with Grade III Hepatic Coma. <i>Artificial Organs</i> , 2001, 25, 109-118.	1.9	9
132	Bone marrow contributes to renal parenchymal turnover and regeneration. <i>Journal of Pathology</i> , 2001, 195, 229-235.	4.5	607
133	Plasmapheresis in Antineutrophil Cytoplasmic Antibodies-Associated Systemic Vasculitis. <i>Therapeutic Apheresis and Dialysis</i> , 2001, 5, 176-181.	0.6	12
134	Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor- $\alpha$ . <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 518-524.	0.7	89
135	Expression and characterization of recombinant rat $\lambda$ 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 253-253.	0.7	43
136	Accelerated Nephrotoxic Nephritis Is Exacerbated in C1q-Deficient Mice. <i>Journal of Immunology</i> , 2001, 166, 6820-6828.	0.8	83
137	Interleukin-11 Attenuates Nephrotoxic Nephritis in Wistar Kyoto Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2310-2320.	6.1	28
138	Oral Administration of Glomerular Basement Membrane Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 61-70.	6.1	39
139	In Goodpasture's Disease, CD4+ T Cells Escape Thymic Deletion and Are Reactive with the Autoantigen $\lambda$ 3(IV)NC1. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1908-1915.	6.1	72
140	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. <i>Journal of Clinical Investigation</i> , 2000, 105, 643-651.	8.2	158
141	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). <i>American Journal of Clinical Pathology</i> , 1999, 111, 507-513.	0.7	539
142	Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. <i>Kidney International</i> , 1999, 55, 1319-1326.	5.2	45
143	Plasma Immunoreactive Leptin Concentration in End-Stage Renal Disease. <i>Clinical Science</i> , 1997, 93, 119-126.	4.3	63
144	T cell responses in ANCA-positive vasculitis. <i>Nephrology</i> , 1997, 3, s778-s779.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. <i>Kidney International</i> , 1997, 51, 222-229.	5.2	104
146	Succinylated gelatin as partial fluid replacement in chronic therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 1992, 7, 124-125.	1.3	0
147	Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. <i>Kidney International</i> , 1991, 40, 757-763.	5.2	314
148	Repeated Membrane Plasma Separation with On-line Sorbent Treatment of Plasma in the Conscious Rat. <i>Artificial Organs</i> , 1986, 10, 135-144.	1.9	13